News
NRXP
4.090
+2.25%
0.090
Weekly Report: what happened at NRXP last week (0622-0626)?
Weekly Report · 1d ago
New to The Street Announces Broadcast of Show #759 on Bloomberg Television Across the U.S., MENA and Latin America tonight 630pm est.
Barchart · 3d ago
NRx Subsidiary HOPE Begins Patient Treatment Using AI-Guided TMS Systems
NASDAQ · 5d ago
NRx Pharmaceuticals Disputes Claims from Kadima
Dow Jones · 5d ago
NRx Pharmaceuticals issues response to Kadima statements
TipRanks · 5d ago
NRx Pharmaceuticals Issues Statement In Response To Kadima Allegations, Citing Arbitration Over Non‑Acquisition By HOPE Therapeutics
Benzinga · 5d ago
NRx Pharmaceuticals pushes Kadima dispute into arbitration amid acquisition lawsuit
PUBT · 5d ago
NRX PHARMACEUTICALS: CO DOES NOT BELIEVE THAT ACQUISITION/NON-ACQUISITION OF ANY INDIVIDUAL CLINIC WOULD BE MATERIAL TO HOPE'S OVERALL BUSINESS MODEL
Reuters · 5d ago
Psychedelic: Definium soars on study results for LSD-based depression treatment
TipRanks · 5d ago
H.C. Wainwright Keeps Their Buy Rating on NRX Pharmaceuticals (NRXP)
TipRanks · 5d ago
NRx Pharma’s HOPE Therapeutics Treats First Patients Using Zeta Surgical's FDA-Cleared Zeta TMS Navigation System
Benzinga · 5d ago
NRx subsidiary HOPE Therapeutics begins patient treatments using Zeta Surgical TMS navigation system
PUBT · 5d ago
NRX PHARMACEUTICALS (NASDAQ: NRXP) SUBSIDIARY HOPE THERAPEUTICS TREATS FIRST PATIENTS USING ZETA SURGICAL'S FDA-CLEARED ZETA TMS NAVIGATION SYSTEM
Reuters · 5d ago
Kadima Neuropsychiatry Institute alleges NRx breached contract
TipRanks · 6d ago
BRIEF-Kadima Neuropsychiatry Institute Files Suit Against NRx Pharmaceuticals
Reuters · 6d ago
KADIMA NEUROPSYCHIATRY INSTITUTE FILES SUIT AGAINST NRX PHARMACEUTICALS (NASDAQ: NRXP), ALLEGING BREACH OF CONTRACT AND MISREPRESENTATION IN CONNECTION WITH ACQUISITION
Reuters · 6d ago
KADIMA NEUROPSYCHIATRY INSTITUTE: LAWSUIT SEEKS SPECIFIC PERFORMANCE IN COURT ORDER COMPELLING DEFENDANTS TO CLOSE DEAL ON TERMS IN EXECUTED AGREEMENT
Reuters · 6d ago
Kadima Neuropsychiatry Institute sues NRx Pharma over alleged breach, misrepresentation in acquisition deal
PUBT · 6d ago
ZETA announces treatment of first patient with Zeta TMS Navigation System
TipRanks · 06/23 19:04
HOPE Therapeutics treats first patient using Zeta TMS Navigation System
PUBT · 06/23 15:05
More
Webull provides a variety of real-time NRXP stock news. You can receive the latest news about Nrx Pharmaceuticals Inc through multiple platforms. This information may help you make smarter investment decisions.
About NRXP
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing therapeutics based on its N-methyl-D-aspartate (NMDA) platform for the treatment of central nervous system disorders, specifically suicidal depression, chronic pain, and PTSD. It is developing NRX-100 (preservative-free intravenous ketamine) and NRX-101, (oral D-cycloserine/lurasidone). NRX-100 has been awarded Fast Track Designation for the treatment of Suicidal Ideation in Depression, including Bipolar Depression. NRX-101 has been awarded Breakthrough Therapy Designation for the treatment of suicidal bipolar depression. NRx has filed an Abbreviated New Drug Application (ANDA) and initiated a New Drug Application filing for NRX-100 (IV ketamine) with an application for the Commissioner’s National Priority Voucher Program for the treatment of suicidal depression. Its subsidiary, HOPE Therapeutics, Inc., is a healthcare delivery company that is building a network of interventional psychiatry clinics.